drugset / Trial / NCT01469182

A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)

NCT01469182

Phase 3 Completed 914 enrolled ALK-Abelló A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This study assessed the safety profile of short ragweed (Ambrosia artemisiifolia) in participants with ragweed-induced rhinoconjunctivitis with or without asthma. The primary objective was to compare treatment-emergent adverse events (AEs) for participants treated with short ragweed allergy immunotherapy tablet (AIT) with those treated with placebo.

Timeline

Start
2011-11
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject SCH 39641 Unknown 12 unknown Other

Indications